CDC advisory panel expected to vote on hepatitis B vaccine for newborns

The Advisory Committee on Immunization Practices (ACIP) voted to change its long-standing guidance on hepatitis B vaccination, marking a significant shift in public health policy. This decision comes after extensive discussions and debates within the committee, reflecting a response to evolving public health needs and concerns about vaccination practices.

Senator Bill Cassidy, R-La., has publicly criticized the CDC's recent decision to roll back its recommendation for the hepatitis B vaccine for newborns, labeling it 'a mistake' that could jeopardize public health. This change follows a series of contentious discussions among CDC advisory panel members, reflecting a significant shift from previous guidelines.

The CDC advisory panel voted to limit hepatitis B vaccinations for newborns, a significant shift reflecting the Trump administration's controversial stance on vaccine guidelines. This decision follows a tumultuous meeting that raised concerns about misinformation and public health implications.

The CDC advisory panel has rolled back its recommendation for the hepatitis B vaccine for newborns, a significant shift from its previous guidelines. This decision follows a series of tumultuous meetings marked by misinformation and debate among panel members regarding the vaccine's necessity and safety.

Senator Bill Cassidy has expressed strong disapproval following a recent vote by a CDC panel that undermines a key vaccine norm he has supported, stating, 'This makes America sicker.' This decision reflects a significant shift in public health policy under Health Secretary Robert F. Kennedy Jr.

A key vaccine panel at the Centers for Disease Control and Prevention (CDC) voted 8-3 to discontinue the recommendation that all newborns receive a first dose of the hepatitis B vaccine. This decision marks a significant shift in public health policy, overturning decades of guidance that aimed to prevent infections and liver cancer in infants.

A federal vaccine advisory committee in the U.S. has voted to discontinue the long-standing recommendation for all newborns to receive the hepatitis B vaccine at birth. This decision marks a significant shift in vaccination policy, reflecting ongoing debates about vaccine administration practices in the country.

A federal advisory panel has voted to remove the longstanding recommendation for hepatitis B vaccinations for newborns, marking a significant shift in public health policy under Health Secretary Robert F. Kennedy Jr. This decision reflects ongoing debates surrounding vaccine recommendations and public health strategies.